|
|||||
|
|
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models |
|
| Authors: | S Betty Yan Victoria L Peek Rose Ajamie Sean G Buchanan Jeremy R Graff Steven A Heidler Yu-Hua Hui Karen L Huss Bruce W Konicek Jason R Manro Chuan Shih Julie A Stewart Trent R Stewart Stephanie L Stout Mark T Uhlik Suzane L Um Yong Wang Wenjuan Wu Lei Yan Wei J Yang Boyu Zhong Richard A Walgren |
| Institution: | 1. Lilly Research Laboratories, Eli Lilly and Company, DC0522, 307 E. McCarty Street, Indianapolis, IN, 46285, USA 2. Formerly at Eli Lilly and Company, currently with Crown Biosciences Inc, Jiangsu, China 3. Formerly at Eli Lilly and Company, currently with Johnson & Johnson, Jiangsu, China |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |